Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03428958 · ClinicalTrials.gov registry record · Phase 1

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

A Phase 1 study of Colorectal Cancer and Colorectal Neoplasms, sponsored by NuCana.

Completed
Registry status
Phase 1
Development phase
111
Enrollment target
10
Study locations

NCT03428958 is a Phase 1 study of Colorectal Cancer and Colorectal Neoplasms that has completed, run by NuCana. The registered enrollment target is 111 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (93% lower). The trial reports 10 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03428958, a Phase 1 study of Colorectal Cancer and Colorectal Neoplasms, has completed, sponsored by NuCana.

COMPLETED
Registry status
Phase 1
Development phase
111 participants
Enrollment target
10
Study locations

Study Summary

This is a three-part study of NUC-3373 administered by intravenous (IV) infusion across two administration schedules, either as monotherapy or as part of various combinations with agents commonly used to treat CRC (leucovorin, oxaliplatin, irinotecan, bevacizumab, cetuximab and panitumumab). The primary objective is to identify a recommended dose and schedule for NUC-3373 when combined with these agents.

Conditions Studied

Colorectal Cancer Colorectal Neoplasms Colorectal Carcinoma Neoplasms, Colorectal Colorectal Tumors

Interventions

  • DRUG NUC-3373 + leucovorin
  • DRUG NUC-3373
  • DRUG NUFOX
  • DRUG NUFOX + VEGF pathway inhibitor
  • DRUG NUFOX + EGFR inhibitor

Study Locations (10)

Other

  • Hopital Franco-Britannique - Levallois-Perret
  • The Beatson West of Scotland Cancer Centre - Glasgow
  • University College London Hospitals NHS Foundation Trust - London
  • University of Oxford - Oxford

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Dana Farber Cancer Institute - Boston

Washington

  • Seattle Cancer Center - Seattle
  • Compass Oncology - Vancouver

North Carolina

  • Duke University Medical Center - Durham

Tennessee

  • Vanderbilt University - Nashville

Trial Details

FieldValue
Enrollment Target 111 participants
Start Date 2018-10-05
Est. Completion 2024-03-21
Phase Phase 1

Sponsor

NuCana

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03428958

The ClinicalTrials.gov registry entry for NCT03428958 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (93% lower). The listed sponsor is NuCana, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which NUC-3373 + leucovorin is the first listed.

NCT03428958 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Other, Massachusetts, Washington.

Frequently Asked Questions

What is clinical trial NCT03428958 about?

NCT03428958 is a clinical study titled "A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment". This is a three-part study of NUC-3373 administered by intravenous (IV) infusion across two administration schedules, either as monotherapy or as part of various combinations with agents commonly used to treat CRC (leucovorin, oxaliplatin, irinotecan, bevacizumab, cetuximab and panitumumab). The pri...

What is the current status of trial NCT03428958?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 111 participants. The study started on 2018-10-05. Estimated completion is 2024-03-21.

What conditions does trial NCT03428958 study?

This clinical trial studies the following conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Neoplasms, Colorectal, Colorectal Tumors.

What interventions are being tested in trial NCT03428958?

The interventions under investigation include: NUC-3373 + leucovorin (DRUG), NUC-3373 (DRUG), NUFOX (DRUG), NUFOX + VEGF pathway inhibitor (DRUG), NUFOX + EGFR inhibitor (DRUG).

Who is sponsoring clinical trial NCT03428958?

This trial is sponsored by NuCana, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03428958 being conducted?

This trial has 10 study locations across Massachusetts, North Carolina, Tennessee, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Colorectal Neoplasms

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.